Shares of Ashford Hospitality Trust, Inc. (NYSE:AHT) [Trend Analysis] runs in leading trade, it moving up 8.11% to traded at $6.93. The firm has price volatility of 5.51% for a week and 3.52% for a month. Its beta stands at 1.49 times. Ashford Hospitality Trust (AHT) responded to FelCor Lodging Trust’s (FCH) ‘misleading comments about value creating proposal’; Ashford Trust seeks constructive dialogue to further explore the important value creating opportunity. Ashford Trust previously reported it submitted a non-binding proposal to acquire FelCor for fixed exchange ratio of 1.192 shares of Ashford Trust per share of FelCor, a total of 400,000 shares of Ashford Inc. (AINC) and a total of 100,000 warrants to purchase Ashford Inc. shares.
“We believe that this proposal provides an attractive value to FelCor shareholders and question what other alternatives would give FelCor shareholders more value than our offer. We believe that FelCor’s February 24th statements regarding Ashford Trust’s value creating proposal are misguided and misleading. We believe there are both immediate and longer term strategic and financial benefits from this combination.”
Ashford Hospitality Trust also acknowledges Land And Buildings endorsement for FelCor Lodging Trust’s Board to review value creating proposal. “We believe shareholders of both FelCor and Ashford Trust are supportive of the transaction and we look forward to engaging with FelCor’s board to further discuss our proposal. Ashford Trust is pleased that shareholders are engaging with FelCor regarding our proposal, which we believe offers compelling strategic, operational, and financial benefits. We believe that there is important opportunity to unlock value for both sets of shareholders through a combined company.”
Narrow down four to firm performance, its weekly performance was -16.54% and monthly performance was -19.27%. The stock price of AHT is moving down from its 20 days moving average with -9.24% and isolated negatively from 50 days moving average with -9.49%.
Sanofi (NYSE:SNY) [Trend Analysis] luring active investment momentum, shares an advance 0.48% to $42.90. French drug giant Sanofi SA (SNY) along with Lonza Group AG reported that they have entered into a strategic partnership to establish a large-scale biologics production facility in Switzerland. The initial investment will be around 290 million Swiss francs or 270 million euros, to be split equally between each company.
Under the partnership in the form of a joint venture, the companies agreed to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility.
The initial phase of the facility will commence construction in 2017, pending necessary regulatory approvals. It is expected to be fully operational by 2020.
Lonza has previously built and licensed three similar facilities in the U.S. and Singapore. The total volume of 362797 shares held in the session was surprisingly higher than its average volume of 1854.40 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 2.20%, and looking further price to next year’s EPS is 6.49%. While take a short look on price to sales ratio, that was 2.98 and price to earnings ratio of 23.63 attracting passive investors.